Clinical Trials Logo

Filter by:
  • Approved for marketing  
  • Page [1]
NCT ID: NCT00683306 Approved for marketing - Clinical trials for Non Small Cell Lung Cancer (NSCLC)

Open Label Extension Study With Gefitinib (IRESSAâ„¢) for Completing Trial Patients Who May Benefit From Further Treatment

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide gefitinib treatment to patients who, on completion or closure of other gefitinib clinical studies, were either receiving placebo treatment, or are continuing on the same dose and regimen of gefitinib established in their preceding study, for as long as the patients continue to derive benefit.

NCT ID: NCT00130897 Approved for marketing - Clinical trials for Carcinoma, Renal Cell

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Start date: July 2005
Phase: N/A
Study type: Expanded Access

The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.

NCT ID: NCT00094029 Approved for marketing - Clinical trials for Gastrointestinal Neoplasm

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Start date: September 2004
Phase: N/A
Study type: Expanded Access

The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies such as A6181004; AND b) patients have GIST which standard treatments have not been able to control with acceptable toxicity AND c) patients have the potential to derive clinical benefit from treatment with SU011248.